Cyclophosphamide

doi:10.1186/1471-2407-7-65

BMC Cancer
Volume 7

Viewing options:

Abstract
Full text
PDF (750KB)

Associated material:

Related literature:

Articles citing this article
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Samaritani R
Corrado G
Vizza E
Sbiroli C

on PubMed

Samaritani R
Corrado G
Vizza E
Sbiroli C
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

Case report

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer

Riccardo Samaritani¹ , Giacomo Corrado² , Enrico Vizza² and Carlo Sbiroli²

¹Division of Medical Oncology, San Carlo IDI Sanità Hospital, Rome, Italy

²Division of Gynaecologic Oncology, National Cancer Institute "Regina Elena", Rome, Italy

author email corresponding author email

BMC Cancer 2007, 7:65doi:10.1186/1471-2407-7-65


Published:	15 April 2007

Abstract

Background

Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status.

Case presentation

We tried palliative chemotherapy with daily low dose oral cyclophosphamide with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide (CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and progression after second line with topotecan.

The progression-free survival time on daily low dose oral cyclophosphamide treatment was 65 months without side effects. She was well during the chemotherapy and lived a normal working and social life.

Conclusion

We think that use of low dose of oral CTX should be investigated further as a strategy against tumour progression after standard chemotherapy in patients who are platinum resistant with poor performance status.